OR WAIT null SECS
March 14, 2025
The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
The company plans to add 16,000 pallet spaces to the 13,000 it already has on site, making for a total of 68,000 pallet spaces covering various temperature requirements.
The company’s US entity, Iwata Label USA, will exhibit its Vial Protect Pack, Light Protect Pack, and Shrink Tack Label.
March 13, 2025
The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.
March 12, 2025
The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).
Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.
In an interview with Pharmaceutical Technology®, Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
March 11, 2025
The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.
Sterimove will make its North American debut at the April 1–3, 2025 event.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments, in an interview with Pharmaceutical Technology®.